<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764110</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-FY2021-6</org_study_id>
    <nct_id>NCT04764110</nct_id>
  </id_info>
  <brief_title>Short-term Impact of Cyplexinol® on Self-reported Joint Pain</brief_title>
  <official_title>Short-term Impact of Cyplexinol® on Inflammatory Status and Related Measures in Men and Women With Self-reported Joint Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Memphis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZyCal Bioceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Memphis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the impact of 900 mg Cyplexinol® taken daily on joint pain over a period of 15&#xD;
      days in comparison with a placebo will be determined using a cross-over double blind design&#xD;
      with a 13 day wash out period. In addition, we will measure cytokine production and related&#xD;
      variables during the two hour after subjects ingest a single dosage of Cyplexinol® or placebo&#xD;
      on days 1 and 15.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic inflammation can induce joint pain, which is a common problem among adult men and&#xD;
      women. ZyCal Bioceuticals is a manufacturer of natural ingredients and finished nutritional&#xD;
      supplements to support bone and joint health in humans. The core ingredient in all ZyCal&#xD;
      products is Cyplexinol® (a Bone Morphogenetic Protein [BMP] Complex). BMP complexes have been&#xD;
      shown to activate mesenchymal stem cells to help the body regenerate osteoblasts and&#xD;
      chondrocytes. BMPs were initially identified in the 1970's as osteogenic factors which&#xD;
      stimulate activation, proliferation, and differentiation of osteoprogenitor cells by binding&#xD;
      BMP receptors and subsequent signaling through the SMAD pathway. BMPs have also been shown to&#xD;
      reduce inflammation and promote healthy inflammatory signaling in joints and other tissues.&#xD;
&#xD;
      Cyplexinol® is delivered in the dietary supplement called Ostinol™, which has been safely&#xD;
      used in oral form by thousands of people since 2007 for bone and joint health. Currently&#xD;
      Cyplexinol® is considered a dietary supplement ingredient and has been awarded GRAS&#xD;
      (generally recognized as safe).&#xD;
&#xD;
      Studies have been conducted to evaluate the safety and efficacy of Cyplexinol® as a dietary&#xD;
      supplement for joint health (Garian, 2012; Scaffidi, 2017). Dosages of 150mg Cyplexinol® have&#xD;
      been compared to a placebo (negative control) alone or in combination with glucosamine&#xD;
      /chondroitin in randomized controlled trials for 4 -12 weeks. Endpoints examined have&#xD;
      included joint stiffness, inflammation, pain, and overall quality of life. However, to date,&#xD;
      no short-term studies have been conducted using Cyplexinol®, nor have any acute studies&#xD;
      evaluated the impact of this agent on immune function.&#xD;
&#xD;
      In this study, the impact of 900 mg Cyplexinol® taken daily on joint pain over a period of 15&#xD;
      days in comparison with a placebo will be determined using a cross-over double blind design&#xD;
      with a 13 day wash out period. In addition, we will measure cytokine production and related&#xD;
      variables during the two hour post ingestion period after subjects ingest a single dosage of&#xD;
      Cyplexinol® or placebo on days 1 and 15.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, control</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>baseline of day 1</time_frame>
    <description>TNF-alpha measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>baseline of day 15</time_frame>
    <description>TNF-alpha measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>60 min after treatment ingestion of day 1</time_frame>
    <description>TNF-alpha measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>60 min after treatment ingestion of day 15</time_frame>
    <description>TNF-alpha measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>120 min after treatment ingestion of day 1</time_frame>
    <description>TNF-alpha measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>120 min after treatment ingestion of day 15</time_frame>
    <description>TNF-alpha measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-6</measure>
    <time_frame>baseline of day 1</time_frame>
    <description>IL-6 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-6</measure>
    <time_frame>baseline of day 15</time_frame>
    <description>IL-6 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-6</measure>
    <time_frame>60 min after treatment ingestion of day 1</time_frame>
    <description>IL-6 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-6</measure>
    <time_frame>60 min after treatment ingestion of day 15</time_frame>
    <description>IL-6 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-6</measure>
    <time_frame>120 min after treatment ingestion of day 1</time_frame>
    <description>IL-6 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-6</measure>
    <time_frame>120 min after treatment ingestion of day 15</time_frame>
    <description>IL-6 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-10</measure>
    <time_frame>baseline of day 1</time_frame>
    <description>IL-10 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-10</measure>
    <time_frame>baseline of day 15</time_frame>
    <description>IL-10 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-10</measure>
    <time_frame>60 min after treatment ingestion of day 1</time_frame>
    <description>IL-10 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-10</measure>
    <time_frame>60 min after treatment ingestion of day 15</time_frame>
    <description>IL-10 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-10</measure>
    <time_frame>120 min after treatment ingestion of day 1</time_frame>
    <description>IL-10 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-10</measure>
    <time_frame>120 min after treatment ingestion of day 15</time_frame>
    <description>IL-10 measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-1beta</measure>
    <time_frame>baseline of day 1</time_frame>
    <description>IL-1beta measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-1beta</measure>
    <time_frame>baseline of day 15</time_frame>
    <description>IL-1beta measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-1beta</measure>
    <time_frame>60 min after treatment ingestion of day 1</time_frame>
    <description>IL-1beta measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-1beta</measure>
    <time_frame>60 min after treatment ingestion of day 15</time_frame>
    <description>IL-1beta measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-1beta</measure>
    <time_frame>120 min after treatment ingestion of day 1</time_frame>
    <description>IL-1beta measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-1beta</measure>
    <time_frame>120 min after treatment ingestion of day 15</time_frame>
    <description>IL-1beta measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>osteocalcin</measure>
    <time_frame>baseline day 1</time_frame>
    <description>osteocalcin measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>osteocalcin</measure>
    <time_frame>baseline day 15</time_frame>
    <description>osteocalcin measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>osteocalcin</measure>
    <time_frame>60 min after treatment ingestion of day 1</time_frame>
    <description>osteocalcin measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>osteocalcin</measure>
    <time_frame>60 min after treatment ingestion of day 15</time_frame>
    <description>osteocalcin measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>osteocalcin</measure>
    <time_frame>120 min after treatment ingestion of day 1</time_frame>
    <description>osteocalcin measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>osteocalcin</measure>
    <time_frame>120 min after treatment ingestion of day 15</time_frame>
    <description>osteocalcin measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>alkaline phosphatase</measure>
    <time_frame>baseline day 1</time_frame>
    <description>alkaline phosphatase measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>alkaline phosphatase</measure>
    <time_frame>baseline day 15</time_frame>
    <description>alkaline phosphatase measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>alkaline phosphatase</measure>
    <time_frame>60 min after treatment ingestion of day 1</time_frame>
    <description>alkaline phosphatase measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>alkaline phosphatase</measure>
    <time_frame>60 min after treatment ingestion of day 15</time_frame>
    <description>alkaline phosphatase measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>alkaline phosphatase</measure>
    <time_frame>120 min after treatment ingestion of day 1</time_frame>
    <description>alkaline phosphatase measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>alkaline phosphatase</measure>
    <time_frame>120 min after treatment ingestion of day 15</time_frame>
    <description>alkaline phosphatase measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Morphogenetic Protein</measure>
    <time_frame>baseline day 1</time_frame>
    <description>Bone Morphogenetic Protein measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Morphogenetic Protein</measure>
    <time_frame>baseline day 15</time_frame>
    <description>Bone Morphogenetic Protein measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Morphogenetic Protein</measure>
    <time_frame>60 min after treatment ingestion of day 1</time_frame>
    <description>Bone Morphogenetic Protein measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Morphogenetic Protein</measure>
    <time_frame>60 min after treatment ingestion of day 15</time_frame>
    <description>Bone Morphogenetic Protein measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Morphogenetic Protein</measure>
    <time_frame>120 min after treatment ingestion of day 1</time_frame>
    <description>Bone Morphogenetic Protein measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Morphogenetic Protein</measure>
    <time_frame>120 min after treatment ingestion of day 15</time_frame>
    <description>Bone Morphogenetic Protein measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Joint pain visual analog scale</measure>
    <time_frame>Day 1 of treatment</time_frame>
    <description>A 100mm visual analog scale will be used to assess joint pain. Scores range from 0 (subject strongly disagreeing with prompt) to 100 (strongly agree).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Joint pain visual analog scale</measure>
    <time_frame>Day 15 of treatment</time_frame>
    <description>A 100mm visual analog scale will be used to assess joint pain. Scores range from 0 (subject strongly disagreeing with prompt) to 100 (strongly agree).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</measure>
    <time_frame>Day 1 of treatment</time_frame>
    <description>The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68) with 0 being none and high values being most.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</measure>
    <time_frame>Day 15 of treatment</time_frame>
    <description>The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68) with 0 being none and high values being most.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary intake</measure>
    <time_frame>Day 1 of treatment</time_frame>
    <description>Dietary intake of subjects for 3-days prior to testing days analyzed using Food Processor Pro software for total calories, macro- and micro-nutrient composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake</measure>
    <time_frame>Day 15 of treatment</time_frame>
    <description>Dietary intake of subjects for 3-days prior to testing days analyzed using Food Processor Pro software for total calories, macro- and micro-nutrient composition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Joint Pain</condition>
  <arm_group>
    <arm_group_label>Cyplexinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg daily (2 capsules) for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules daily for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cyplexinol</intervention_name>
    <description>partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)</description>
    <arm_group_label>Cyplexinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  body mass index (BMI) between 18-29.9 kg/m2 (not obese)&#xD;
&#xD;
          -  no consumption of alcohol-containing beverages within 48 hours of testing&#xD;
&#xD;
          -  experiencing self-reported joint pain with a minimum pain rating of 3/10 for at least&#xD;
             the past 30 days&#xD;
&#xD;
          -  engaged in structured exercise 2 or more days per week for the past 6 months or longer&#xD;
&#xD;
          -  a negative verbal pre-study drug screen (alcohol abuse, amphetamines, benzodiazepines,&#xD;
             cocaine, opioids, phencyclidine, barbiturates, cotinine), no history of use of illicit&#xD;
             drugs or other substances of abuse within 12 months of the screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  tobacco user&#xD;
&#xD;
          -  active infection or illness of any kind&#xD;
&#xD;
          -  rheumatic or osteoarthritic diagnosis&#xD;
&#xD;
          -  Using anti-inflammatory medicines, pain medications, or dietary supplements (or not&#xD;
             willing to cease for one-month prior to participation and throughout study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Bloomer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Memphis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacquelyn Pence, PhD</last_name>
    <phone>901-678-1547</phone>
    <email>jpence1@memphis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Nutraceutical and Dietary Supplement Reseach</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38152</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Pence, PhD</last_name>
      <phone>901-678-1547</phone>
      <email>jpence1@memphis.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Memphis</investigator_affiliation>
    <investigator_full_name>Richard Bloomer</investigator_full_name>
    <investigator_title>Dean of the College of Health Sciences</investigator_title>
  </responsible_party>
  <keyword>Cyplexinol</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

